Universities in Germany and Sweden Lose Access to Elsevier Journals

Consortia in both countries are pushing for open-access subscriptions with the publisher.

| 3 min read

ISTOCK, DOYATA

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

This month, approximately 300 academic institutions in Germany and Sweden lost access to new papers published in Elsevier’s journals due to a standstill in negotiations for nationwide subscription contracts. While Elsevier’s papers remain inaccessible, academics are turning to alternative means of obtaining them, such as using inter-library loan services, emailing authors, finding earlier versions on preprint servers, or buying individual papers.

“Of course, we can’t deny that it’s a loss not being able to have a complete [collection] of scientific papers in front of you and just screen through them,” says Anders Götherström, an archeologist at Stockholm University. “But I imagine eventually, we will still find a way to get the papers that we want to get.”

Josef Pfeilschifter, a pharmacologist and toxicologist at Goethe University Frankfurt, is very concerned about the loss of access to Elsevier’s journals at his institution. “For life scientists and medical scientists, [Elsevier’s titles include] ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Diana Kwon

    Diana is a freelance science journalist who covers the life sciences, health, and academic life.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Discover a serum-free way to produce dendritic cells and macrophages for cell therapy applications.

Optimizing In Vitro Production of Monocyte-Derived Dendritic Cells and Macrophages

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with Lipid Nanoparticles

Thermo Fisher Logo